Skip to main content

Advertisement

Table 1 Randomised patient characteristics at baseline

From: Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory study

  Chondroitin sulfate (n = 97) Celecoxib (n = 97)
Female 53 (54.6) 61 (62.9)
Age (years) 61.4 ± 9.3 61.3 ± 8.5
Body mass index (kg/m2) 30.1 ± 5.8 32.3 ± 5.8
At least one previous medical condition 86 (88.7) 86 (88.7)
At least one active medical condition 96 (99.0) 97 (100.0)
Cartilage volume (mm3)
 Lateral compartment 4613 ± 1755 4405 ± 1157
  Condyle 2621 ± 1073 2476 ± 716
  Plateau 1993 ± 799 1930 ± 540
 Medial compartment 4515 ± 1537 4255 ± 1217
  Condyle 2807 ± 971 2646 ± 779
  Plateau 1708 ± 623 1609 ± 489
Synovial membrane thickness (mm) 1.0 ± 0.2 1.0 ± 0.2
BML score (global knee)a 2.6 ± 3.0 2.7 ± 2.5
Synovial fluid volume (ml) 13.8 ± 14.6 10.8 ± 10.9
Joint swelling and effusion
  Swelling 76 (78.4) 78 (80.4)
  Effusion 76 (78.4) 71 (73.2)
  Both 59 (60.8) 55 (56.7)
Pain VAS (mm)a 62.42 ± 15.51 59.26 ± 18.10
WOMACa
  Total score (0–240) 124.9 ± 38.1 126.7 ± 43.9
  Pain score (0–50) 25.6 ± 8.1 25.5 ± 9.0
  Stiffness score (0–20) 10.8 ± 3.7 11.7 ± 4.3
  Physical function score (0–170) 88.5 ± 28.7 89.5 ± 32.5
Quality of life (SF-36)a
  Physical component summary 35.4 ± 7.8 35.7 ± 8.1
  Mental component summary 51.7 ± 9.5 52.7 ± 11.0
  1. Data shown as number of patients (%) or mean ± standard deviation
  2. aData were not available for two patients in the chondroitin sulfate group
  3. BML bone marrow lesion, SF-36 Short Form-36, VAS visual analogue scale, WOMAC Western Ontario and McMaster Universities Osteoarthritis Index